PH26284A - Antiviral or antibacterial composition and method of use thereof - Google Patents

Antiviral or antibacterial composition and method of use thereof Download PDF

Info

Publication number: PH26284A
Authority: PH; Philippines
Prior art keywords: composition; dimer; lysozyme; treating; ribonuclease
Prior art date: 1988-05-26

Application number

PH38684A

Other languages

English (en)

Inventor

Witold Kiczka

Original Assignee

Nika Health Products Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-05-26

Filing date

1989-05-23

Publication date

1992-04-10

1989-05-23 Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd

1992-04-10 Publication of PH26284A publication Critical patent/PH26284A/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 56
238000000034 method Methods 0.000 title claims abstract description 29
230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 10
230000000840 anti-viral effect Effects 0.000 title claims abstract description 9
235000010335 lysozyme Nutrition 0.000 claims abstract description 98
102000016943 Muramidase Human genes 0.000 claims abstract description 97
108010014251 Muramidase Proteins 0.000 claims abstract description 97
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 97
229960000274 lysozyme Drugs 0.000 claims abstract description 97
239000004325 lysozyme Substances 0.000 claims abstract description 97
230000001472 cytotoxic effect Effects 0.000 claims abstract description 26
231100000433 cytotoxic Toxicity 0.000 claims abstract description 24
241000282414 Homo sapiens Species 0.000 claims abstract description 10
239000003937 drug carrier Substances 0.000 claims abstract description 9
239000000539 dimer Substances 0.000 claims description 93
108020002230 Pancreatic Ribonuclease Proteins 0.000 claims description 24
102000005891 Pancreatic ribonuclease Human genes 0.000 claims description 24
241001465754 Metazoa Species 0.000 claims description 15
239000002674 ointment Substances 0.000 claims description 14
230000003612 virological effect Effects 0.000 claims description 13
239000000243 solution Substances 0.000 claims description 12
208000015181 infectious disease Diseases 0.000 claims description 11
108010015937 ribonuclease dimer Proteins 0.000 claims description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
208000004396 mastitis Diseases 0.000 claims description 8
206010046914 Vaginal infection Diseases 0.000 claims description 6
208000035143 Bacterial infection Diseases 0.000 claims description 5
206010052428 Wound Diseases 0.000 claims description 5
208000027418 Wounds and injury Diseases 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 4
208000022362 bacterial infectious disease Diseases 0.000 claims description 4
230000037396 body weight Effects 0.000 claims description 4
208000005141 Otitis Diseases 0.000 claims description 3
208000036142 Viral infection Diseases 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
208000019258 ear infection Diseases 0.000 claims description 3
239000012266 salt solution Substances 0.000 claims description 3
239000011780 sodium chloride Substances 0.000 claims description 3
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
238000002347 injection Methods 0.000 claims description 2
239000007924 injection Substances 0.000 claims description 2
239000000829 suppository Substances 0.000 claims description 2
208000015898 Bacterial Skin disease Diseases 0.000 claims 1
208000012544 Viral Skin disease Diseases 0.000 claims 1
102000004190 Enzymes Human genes 0.000 abstract description 26
108090000790 Enzymes Proteins 0.000 abstract description 26
229940088598 enzyme Drugs 0.000 abstract description 26
102000006382 Ribonucleases Human genes 0.000 abstract description 25
108010083644 Ribonucleases Proteins 0.000 abstract description 25
208000031295 Animal disease Diseases 0.000 abstract 1
238000011282 treatment Methods 0.000 description 35
238000012360 testing method Methods 0.000 description 33
201000010099 disease Diseases 0.000 description 28
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
210000004027 cell Anatomy 0.000 description 24
230000000694 effects Effects 0.000 description 23
239000000178 monomer Substances 0.000 description 21
241000282472 Canis lupus familiaris Species 0.000 description 18
210000002950 fibroblast Anatomy 0.000 description 18
230000001580 bacterial effect Effects 0.000 description 15
230000003013 cytotoxicity Effects 0.000 description 13
231100000135 cytotoxicity Toxicity 0.000 description 13
235000013601 eggs Nutrition 0.000 description 13
208000024891 symptom Diseases 0.000 description 12
241000283690 Bos taurus Species 0.000 description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
230000035755 proliferation Effects 0.000 description 9
241000711408 Murine respirovirus Species 0.000 description 7
238000011534 incubation Methods 0.000 description 7
238000011160 research Methods 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
241000894006 Bacteria Species 0.000 description 6
241000194017 Streptococcus Species 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
241000700605 Viruses Species 0.000 description 5
239000008267 milk Substances 0.000 description 5
235000013336 milk Nutrition 0.000 description 5
210000004080 milk Anatomy 0.000 description 5
241000867607 Chlorocebus sabaeus Species 0.000 description 4
230000036528 appetite Effects 0.000 description 4
235000019789 appetite Nutrition 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000012530 fluid Substances 0.000 description 4
230000035931 haemagglutination Effects 0.000 description 4
230000001771 impaired effect Effects 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
231100001231 less toxic Toxicity 0.000 description 4
230000001717 pathogenic effect Effects 0.000 description 4
230000008961 swelling Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
208000035473 Communicable disease Diseases 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
208000001688 Herpes Genitalis Diseases 0.000 description 3
208000007514 Herpes zoster Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
241000589517 Pseudomonas aeruginosa Species 0.000 description 3
241000193985 Streptococcus agalactiae Species 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
244000052616 bacterial pathogen Species 0.000 description 3
230000036760 body temperature Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
201000004946 genital herpes Diseases 0.000 description 3
210000004392 genitalia Anatomy 0.000 description 3
230000009931 harmful effect Effects 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
231100000065 noncytotoxic Toxicity 0.000 description 3
239000012188 paraffin wax Substances 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
206010004142 Bartholinitis Diseases 0.000 description 2
241000701931 Canine parvovirus Species 0.000 description 2
206010049583 Douglas' abscess Diseases 0.000 description 2
206010017553 Furuncle Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
208000008071 Parvoviridae Infections Diseases 0.000 description 2
206010057343 Parvovirus infection Diseases 0.000 description 2
229920001214 Polysorbate 60 Polymers 0.000 description 2
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
206010041925 Staphylococcal infections Diseases 0.000 description 2
241000194042 Streptococcus dysgalactiae Species 0.000 description 2
201000002014 Suppurative Otitis Media Diseases 0.000 description 2
208000000558 Varicose Ulcer Diseases 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
238000002266 amputation Methods 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000003385 bacteriostatic effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000012258 culturing Methods 0.000 description 2
230000003292 diminished effect Effects 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000002350 laparotomy Methods 0.000 description 2
208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 2
210000002445 nipple Anatomy 0.000 description 2
230000002980 postoperative effect Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
208000017520 skin disease Diseases 0.000 description 2
230000008673 vomiting Effects 0.000 description 2
-1 Acetylstearoyloxy alcohol Chemical compound 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
206010002942 Apathy Diseases 0.000 description 1
208000031462 Bovine Mastitis Diseases 0.000 description 1
241000224483 Coccidia Species 0.000 description 1
208000005156 Dehydration Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
101001013832 Homo sapiens Mitochondrial peptide methionine sulfoxide reductase Proteins 0.000 description 1
206010021531 Impetigo Diseases 0.000 description 1
241001313288 Labia Species 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
102100031767 Mitochondrial peptide methionine sulfoxide reductase Human genes 0.000 description 1
108700022034 Opsonin Proteins Proteins 0.000 description 1
206010033733 Papule Diseases 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
241000588769 Proteus <enterobacteria> Species 0.000 description 1
241000588767 Proteus vulgaris Species 0.000 description 1
206010037569 Purulent discharge Diseases 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
208000033809 Suppuration Diseases 0.000 description 1
206010042731 Sycosis barbae Diseases 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
206010000496 acne Diseases 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000009200 cobalt therapy Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
201000009101 diabetic angiopathy Diseases 0.000 description 1
201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000009088 enzymatic function Effects 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
235000015220 hamburgers Nutrition 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000037189 immune system physiology Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000002122 leukaemogenic effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000001589 microsome Anatomy 0.000 description 1
230000027939 micturition Effects 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
239000003921 oil Substances 0.000 description 1
210000004923 pancreatic tissue Anatomy 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
230000002399 phagocytotic effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000000843 powder Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
229940007042 proteus vulgaris Drugs 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
239000000523 sample Substances 0.000 description 1
230000035807 sensation Effects 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229940115920 streptococcus dysgalactiae Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
239000006216 vaginal suppository Substances 0.000 description 1
230000010148 water-pollination Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PH38684A 1988-05-26 1989-05-23 Antiviral or antibacterial composition and method of use thereof PH26284A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US17858888A	1988-05-26	1988-05-26
PCT/US1988/001785 WO1989011294A1 (en)	1988-05-26	1988-05-26	Antiviral or antibacterial compound and method of use
OA59731A OA09785A (en)	1988-05-26	1990-01-26	Antiviral or antibacterial compound and method of use

Publications (1)

Publication Number	Publication Date
PH26284A true PH26284A (en)	1992-04-10

Family

ID=33162813

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH38684A PH26284A (en)	1988-05-26	1989-05-23	Antiviral or antibacterial composition and method of use thereof

Country Status (23)

Country	Link
US (3)	US5200182A (de)
EP (1)	EP0380484B1 (de)
JP (1)	JPH0649659B2 (de)
AT (1)	ATE93143T1 (de)
AU (1)	AU624331B2 (de)
BG (1)	BG60544B1 (de)
CA (1)	CA1335425C (de)
CS (1)	CS277030B6 (de)
DK (1)	DK173078B1 (de)
ES (1)	ES2011577A6 (de)
FI (1)	FI900412A0 (de)
HK (1)	HK42394A (de)
HU (1)	HU204710B (de)
IL (1)	IL90092A (de)
LV (1)	LV10054B (de)
MA (1)	MA21560A1 (de)
MW (1)	MW390A1 (de)
OA (1)	OA09785A (de)
PH (1)	PH26284A (de)
RU (1)	RU2092183C1 (de)
WO (1)	WO1989011294A1 (de)
YU (1)	YU109289A (de)
ZA (1)	ZA893382B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0380484B1 (de) *	1988-05-26	1993-08-18	Nika Health Products Limited	Verwendung eines Lysozymdimeren und/oder Ribonucleasedimeren zur Herstellung eines antiviralen oder antibakteriellen Arzneimittels
JP2732515B2 (ja) *	1990-01-08	1998-03-30	ニカヘルスプロダクツリミテッド	リボヌクレアーゼ二量体の製造方法
US5989880A (en)	1990-01-08	1999-11-23	Nika Health Products Ltd.	Method of preparing lysozyme dimers
PL173978B1 (pl) *	1992-07-13	1998-05-29	Nika Health Products Ltd	Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej
CH682541A5 (de) *	1992-06-23	1993-10-15	Urs Viktor Dr Wirth	Biochemische Inaktivierung von RNA-Viren.
US6183742B1 (en)	1992-07-13	2001-02-06	Nika Health Products, Limited	Applications of lysozyme dimer
DZ1964A1 (fr) *	1995-01-13	2002-10-15	Nika Health Products Ltd	Nouvelle applications d'un dimère de lysozyme.
GB2304048A (en) *	1995-08-12	1997-03-12	John William Carson	Medicament containing saliva extract
US6123937A (en) *	1997-03-14	2000-09-26	Nika Health Products, Limited	Applications of lysozyme dimer
RU2157206C1 (ru) *	1999-03-10	2000-10-10	Оренбургская государственная медицинская академия	Бактерицидный отогель
RU2172179C2 (ru) *	1999-06-24	2001-08-20	Сельков Сергей Алексеевич	Шарики "биосан" для лечения кольпитов различного генеза и способ лечения кольпитов различного генеза
RU2191576C2 (ru) *	1999-07-27	2002-10-27	Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии	Способ лечения субклинической формы генитальной герпесвирусной инфекции у женщин
RU2200550C2 (ru) *	1999-10-29	2003-03-20	Научно-исследовательская лаборатория иммунохимиотерапии лепры и иммунотропных средств с клиникой и опытно-экспериментальным производством	Новые лекарственные формы димоцифона в терапии лепры, зудящих и аллергодерматозов, герпетиформного дерматита дюринга
RU2163119C1 (ru) *	2000-04-26	2001-02-20	Свистов Виталий Владимирович	Антисептическое средство
RU2180593C1 (ru) *	2000-11-08	2002-03-20	Айламазян Эдуард Карпович	Фармацевтическая композиция для лечения и профилактики генитального герпеса, хронической папилломы вирусной инфекции и профилактики рака шейки матки (варианты)
US6716813B2 (en) *	2000-11-28	2004-04-06	House Ear Institute	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US7338936B2 (en) *	2000-11-28	2008-03-04	House Ear Institute	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
RU2177781C1 (ru) *	2000-12-06	2002-01-10	Научный Центр Здоровья детей РАМН	Суппозитории ректальные, содержащие витаминный комплекс
JP2002187853A (ja) *	2000-12-21	2002-07-05	Shinei Ferumentekku:Kk	動物の乳頭除菌剤および菌環境改善方法
RU2195927C1 (ru) *	2001-07-13	2003-01-10	ООО "Тенториум"	Абиес-свеча "канделла-два"
DE10210285A1 (de) *	2002-03-08	2003-11-13	Medigene Ag	Reversibles Toxin und seine Verwendung
US8470315B2 (en) *	2004-04-13	2013-06-25	Quintessence Biosciences, Inc.	Non-natural ribonuclease conjugates as cytotoxic agents
US20050244402A1 (en) *	2004-04-30	2005-11-03	Villanueva Julie M	Absorption of pain-causing agents
US7348301B2 (en) *	2006-02-16	2008-03-25	Buckman Laboratories International, Inc.	Lysozyme-based method and composition to control the growth of microorganisms in aqueous systems
EP2044097A4 (de) *	2006-06-23	2010-10-06	Quintessence Biosciences Inc	Modifizierte ribonukleasen
US8298801B2 (en)	2006-07-17	2012-10-30	Quintessence Biosciences, Inc.	Methods and compositions for the treatment of cancer
RU2009136424A (ru) *	2007-03-02	2011-04-10	СЕНТ СИМЕОН ЭлДиЭй (US)	Композиция и способ лечения папилломавируса и саркоидов лошадей
WO2009036000A2 (en) *	2007-09-11	2009-03-19	University Of Maryland, Baltimore	Methods of treating a microbial infection by modulating rnase-l expression and/or activity
JP2010540681A (ja) *	2007-10-08	2010-12-24	クインテッセンスバイオサイエンシズ，インコーポレーテッド	リボヌクレアーゼに基づく治療のための組成物及び方法
US8029782B2 (en)	2008-10-01	2011-10-04	Quintessence Biosciences, Inc.	Therapeutic ribonucleases
US20100215707A1 (en) *	2009-02-25	2010-08-26	Mcdonald Thomas	Activated creatinine and precursors thereof as antibacterial agents, compositions and products containing such agents and uses thereof
NZ600269A (en)	2009-05-20	2014-02-28	Dec Int Nz Ltd	Delivery device for treatment of mastitis
PL2457576T3 (pl)	2010-11-29	2021-04-06	Eurochit Danuta Kruszewska	Szczep Lactobacillus reuteri do stosowania medycznego i weterynaryjnego w profilaktyce oraz w leczeniu zespołu metabolicznego lub infekcji
RU2548803C2 (ru) *	2011-11-28	2015-04-20	Общество с ограниченной ответственностью " Фарматренд"	ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ ИНФЕКЦИЙ P. Aeruginosa, СОДЕРЖАЩАЯ РЕКОМБИНАНТНЫЙ ЛИЗОЦИМ
RU2509801C2 (ru) *	2012-03-22	2014-03-20	Борис Михайлович Куриненко	СПОСОБ ИСПОЛЬЗОВАНИЯ РИБОНУКЛЕАЗЫ Bacillus intermedius
KR20150027152A (ko)	2012-05-29	2015-03-11	다누타 크루셰프스카	인간 및 동물 모두에서 예방 및 의약에 유용한 락토바실러스 류테리 ｄａｎ080을 포함하는 나노프로덕트 및 이의 의학적 용도
EP2674162A1 (de)	2012-05-29	2013-12-18	Danuta Kruszewska	Nanoprodukt, beinhaltend lactobacillus reuteri dan080, zur verwendung bei der prophylaxe, diagnose sowie bei der medizinischen and veterinärmedizinischen behandlung
RU2504397C1 (ru) *	2012-10-25	2014-01-20	Леонид Леонидович Клопотенко	Фармацевтическая композиция, содержащая фермент рибонуклеазу и глицирризиновую кислоту или ее соли: глицирризинат аммония, или дикалия, или тринатрия
US9573980B2 (en)	2013-03-15	2017-02-21	Spogen Biotech Inc.	Fusion proteins and methods for stimulating plant growth, protecting plants from pathogens, and immobilizing Bacillus spores on plant roots
US9950075B2 (en)	2013-03-15	2018-04-24	The University Of Massachusetts	Compositions and methods for delivering agents to the central nervous system
WO2015125961A1 (ja) *	2014-02-21	2015-08-27	国立大学法人東京海洋大学	ノロウィルス不活化剤及びその製造方法、ノロウィルス不活化方法、ノロウィルス不活化用リゾチーム類の製造方法、ノロウィルス感染の予防薬又は治療薬、並びにノロウィルス不活化用皮膚外用剤
WO2016017784A1 (ja) *	2014-07-31	2016-02-04	キユーピー株式会社	含水流動状組成物及びその製造方法、並びに、リゾチーム加工品及び／又はその塩並びにその製造方法
IL315468A (en)	2014-09-17	2024-11-01	Spogen Biotech Inc	Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
LV15071B (lv) *	2015-07-14	2016-02-20	Rīgas Stradiņa Universitāte	Kompozīcija subklīniska mastīta ārstēšanai govīm
RU2634264C1 (ru) *	2016-09-19	2017-10-24	Александр Ливиевич Ураков	Крем-молочко для лечения опоясывающего лишая
CN110088650B (zh)	2016-12-28	2021-09-07	Dic株式会社	分散体和使用其的喷墨用油墨组合物、光转换层、和液晶显示元件
WO2019060574A1 (en)	2017-09-20	2019-03-28	Spogen Biotech Inc.	FUSION PROTEINS, RECOMBINANT BACTERIA AND EXIN FRAGMENTS FOR PLANT HEALTH
WO2021021765A1 (en) *	2019-07-26	2021-02-04	Evolve Biosystems, Inc.	Nutritive compositions with bioactive proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1268M (fr) *	1961-06-29	1962-04-24	Puiseux	Médicament antimitotique et antiviral.
FR4020M (de) *	1965-01-29	1966-03-21
DE1517751C3 (de) *	1965-07-08	1975-02-27	Eisai Co., Ltd., Tokio	Verfahren zum Verhindern der Bildung von flockigen Lysozym- und/oder Lysozymsalzniederschlägen in wässrigen Lösungen, die Lysozym und/oder Lysozymsalze enthalten
DE1545644A1 (de) *	1965-12-06	1969-08-07	Boehringer Sohn Ingelheim	Verfahren zur Herstellung von neuen quaternaeren Scopolammoniumsalzen
GB1110504A (en) *	1966-03-18	1968-04-18	Prodotti Antibiotici Spa	Pharmaceutical compositions
US4221794A (en) *	1979-06-21	1980-09-09	Newport Pharmaceuticals International, Inc.	Method of imparting immunomodulating and antiviral activity
US4510144A (en) *	1981-08-26	1985-04-09	Newport Pharmaceuticals International	Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives
CA1263378A (en) *	1985-01-08	1989-11-28	Robert James Alaimo	Imidazo¬4,5-f\|quinolines useful as immunomodulating agents
US4739046A (en) *	1985-08-19	1988-04-19	Luzio Nicholas R Di	Soluble phosphorylated glucan
US4744984A (en) *	1985-10-08	1988-05-17	Vetrepharm Research, Inc.	Antiviral immunotherapeutic agent and preparation thereof
EP0380484B1 (de) *	1988-05-26	1993-08-18	Nika Health Products Limited	Verwendung eines Lysozymdimeren und/oder Ribonucleasedimeren zur Herstellung eines antiviralen oder antibakteriellen Arzneimittels

1988
- 1988-05-26 EP EP88905146A patent/EP0380484B1/de not_active Expired - Lifetime
- 1988-05-26 HU HU883981A patent/HU204710B/hu unknown
- 1988-05-26 RU SU884743095A patent/RU2092183C1/ru active
- 1988-05-26 FI FI900412A patent/FI900412A0/fi not_active IP Right Cessation
- 1988-05-26 JP JP63504463A patent/JPH0649659B2/ja not_active Expired - Fee Related
- 1988-05-26 WO PCT/US1988/001785 patent/WO1989011294A1/en not_active Ceased
- 1988-05-26 AT AT88905146T patent/ATE93143T1/de not_active IP Right Cessation
- 1988-05-26 AU AU19408/88A patent/AU624331B2/en not_active Expired
- 1988-05-26 US US07/459,738 patent/US5200182A/en not_active Expired - Lifetime
1989
- 1989-04-20 CA CA000597341A patent/CA1335425C/en not_active Expired - Fee Related
- 1989-04-27 IL IL9009289A patent/IL90092A/en not_active IP Right Cessation
- 1989-05-08 ZA ZA893382A patent/ZA893382B/xx unknown
- 1989-05-16 ES ES8901637A patent/ES2011577A6/es not_active Expired - Fee Related
- 1989-05-23 PH PH38684A patent/PH26284A/en unknown
- 1989-05-24 MA MA21811A patent/MA21560A1/fr unknown
- 1989-05-26 CS CS893180A patent/CS277030B6/cs not_active IP Right Cessation
- 1989-05-26 YU YU01092/89A patent/YU109289A/xx unknown
1990
- 1990-01-22 MW MW3/90A patent/MW390A1/xx unknown
- 1990-01-22 DK DK199000168A patent/DK173078B1/da not_active IP Right Cessation
- 1990-01-26 OA OA59731A patent/OA09785A/en unknown
- 1990-02-22 BG BG91270A patent/BG60544B1/bg unknown
1992
- 1992-04-08 US US07/865,002 patent/US5466449A/en not_active Expired - Lifetime
- 1992-12-28 LV LVP-92-508A patent/LV10054B/en unknown
1994
- 1994-05-05 HK HK42394A patent/HK42394A/en not_active IP Right Cessation
1995
- 1995-06-07 US US08/474,663 patent/US6099835A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HU883981D0 (en)	1990-12-28
IL90092A (en)	1995-03-30
BG91270A (bg)	1993-12-24
RU2092183C1 (ru)	1997-10-10
LV10054A (lv)	1994-05-10
ATE93143T1 (de)	1993-09-15
MW390A1 (en)	1990-11-14
WO1989011294A1 (en)	1989-11-30
US5200182A (en)	1993-04-06
EP0380484A1 (de)	1990-08-08
HK42394A (en)	1994-05-13
FI900412A7 (fi)	1990-01-25
CS318089A3 (en)	1992-05-13
BG60544B1 (en)	1995-08-28
CA1335425C (en)	1995-05-02
FI900412A0 (fi)	1990-01-25
YU109289A (en)	1991-08-31
OA09785A (en)	1994-04-15
DK173078B1 (da)	1999-12-20
JPH03504121A (ja)	1991-09-12
EP0380484B1 (de)	1993-08-18
LV10054B (en)	1995-02-20
HUT54060A (en)	1991-01-28
DK16890A (da)	1990-01-22
MA21560A1 (fr)	1989-12-31
ZA893382B (en)	1991-01-30
AU624331B2 (en)	1992-06-11
HU204710B (en)	1992-02-28
ES2011577A6 (es)	1990-01-16
US5466449A (en)	1995-11-14
DK16890D0 (da)	1990-01-22
JPH0649659B2 (ja)	1994-06-29
CS277030B6 (en)	1992-11-18
US6099835A (en)	2000-08-08
AU1940888A (en)	1989-12-12

Publication	Publication Date	Title
US5200182A (en)	1993-04-06	Antiviral or antibacterial composition and method of use
US20120245132A1 (en)	2012-09-27	Composition Comprising Benzoic Acid in Combination with Organic Acid Preservatives as Active Ingredients and the Use Thereof
CN109985069B (zh)	2021-03-23	益生菌组合物及其用途
US6132715A (en)	2000-10-17	Method of inhibiting biosynthesis of tumor necrosis factor
CN114767708A (zh)	2022-07-22	一种稳定的妇科抑菌组合物及妇科护理液
CN114652748A (zh)	2022-06-24	一种含有干细胞抑菌因子的医用妇科洗液的制备方法及其应用
US5342612A (en)	1994-08-30	Compositions for the treatment of mammalian diseases
CN113143862A (zh)	2021-07-23	富马酸二甲酯滴眼液及其制备方法和作为真菌性角膜炎治疗药物的应用
KR930004599B1 (ko)	1993-06-01	항바이러스성 또는 항균성 조성물
DE3883392T2 (de)	1994-02-24	Verwendung eines Lysozymdimeren und/oder Ribonucleasedimeren zur Herstellung eines antiviralen oder antibakteriellen Arzneimittels.
CN105560374A (zh)	2016-05-11	一种用于治疗奶牛乳腺炎的复方制剂及其制备方法
Cox	1973	Cefazolin therapy of urinary tract infections
RO110037B1 (ro)	1995-09-29	Compoziții antivirale sau antibacteriene și metodă de tratare a infecțiilor, cu acestea
Iyengar et al.	1966	Plumbago zeylanica L.(Chitrak) a gastrointestinal flora normaliser
Powell, SJ & MacLeod	1966	Ambilhar, a nitrothiazole derivative, in urinary tract bilharzia
JOHNSON	1948	Dermatologic evaluation of yeast, tyrothricin, chlorophyll and nitrofurazone